AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer

Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program

Dabur India updates on Q1 FY25

Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25

Central Council for Research in Ayurvedic Sciences launches ‘PRAGATI-2024’

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million

Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery

Merck 1Q 2024 sales up 9% to US$ 15.8 billion

Sales reflect continued strong growth in oncology and vaccines

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms